Skip to main content
. Author manuscript; available in PMC: 2021 Apr 28.
Published in final edited form as: J Am Coll Cardiol. 2020 Apr 28;75(16):1956–1974. doi: 10.1016/j.jacc.2020.02.056

FIGURE 1. Physiologic Mechanisms of Novel Pharmacologic Agents for Diabetes.

FIGURE 1

Both SGLT2i and GLPRA have effects on multiple organs in the body, modulating not only glycemic control but lipogenesis, satiety, smooth muscle tone, and renal filtration. From top to bottom, the pancreas, pancreatic islet cells, liver, skeletal muscle adipocytes, heart, vasculature, kidneys, central nervous system, and gastrointestinal track are affected by these molecules. Up and down arrows denote whether a process is increased or decreased by each medication. Directional arrows denote the proposed effects of modulations in these processes. GLPRA = glucagon-like peptide 1 receptor agonist; FA = ■■■; FFA = ■■■; NAFLD = ■■■; Na/H = ■■■; SGLT2i = sodium glucose cotransporter 2 inhibitor; SNS = ■■■; TG = ■■■.